CR20140575A - Proceso de aislamiento / purificación de células tumorales y métodos del uso del mismo - Google Patents
Proceso de aislamiento / purificación de células tumorales y métodos del uso del mismoInfo
- Publication number
- CR20140575A CR20140575A CR20140575A CR20140575A CR20140575A CR 20140575 A CR20140575 A CR 20140575A CR 20140575 A CR20140575 A CR 20140575A CR 20140575 A CR20140575 A CR 20140575A CR 20140575 A CR20140575 A CR 20140575A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- tumor cells
- insulation
- purification process
- assays
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 210000004881 tumor cell Anatomy 0.000 title abstract 2
- 238000009413 insulation Methods 0.000 title 1
- 238000000746 purification Methods 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940041181 antineoplastic drug Drugs 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002489 hematologic effect Effects 0.000 abstract 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 abstract 1
- 238000003367 kinetic assay Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647248P | 2012-05-15 | 2012-05-15 | |
| PCT/US2013/031300 WO2013172955A1 (en) | 2012-05-15 | 2013-03-14 | Tumor cell isolation/purification process and methods for use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20140575A true CR20140575A (es) | 2015-05-07 |
Family
ID=49584132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20140575A CR20140575A (es) | 2012-05-15 | 2014-12-12 | Proceso de aislamiento / purificación de células tumorales y métodos del uso del mismo |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20150160193A1 (enExample) |
| EP (1) | EP2850434A4 (enExample) |
| JP (1) | JP2015517662A (enExample) |
| KR (1) | KR20150035537A (enExample) |
| CN (1) | CN104704368A (enExample) |
| AU (1) | AU2013263337A1 (enExample) |
| BR (1) | BR112014028396A2 (enExample) |
| CA (1) | CA2873180A1 (enExample) |
| CO (1) | CO7240391A2 (enExample) |
| CR (1) | CR20140575A (enExample) |
| HK (1) | HK1208727A1 (enExample) |
| IL (1) | IL235709A0 (enExample) |
| IN (1) | IN2014DN09582A (enExample) |
| MX (1) | MX2014013939A (enExample) |
| SG (1) | SG11201407497TA (enExample) |
| TW (1) | TW201409029A (enExample) |
| WO (1) | WO2013172955A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12324657B2 (en) | 2007-11-28 | 2025-06-10 | Intervet Inc. | System and method for diagnosis of bovine diseases using auscultation analysis |
| US9476871B2 (en) | 2012-05-02 | 2016-10-25 | Diatech Oncology Llc | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
| WO2014123732A1 (en) * | 2013-02-06 | 2014-08-14 | Pierson Precision Auscultation | System and method for determining antibiotic effectiveness in respiratory diseased using auscultation analysis |
| JP6841656B2 (ja) * | 2013-12-17 | 2021-03-10 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法 |
| WO2016205320A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
| SMT202100416T1 (it) | 2016-03-02 | 2021-09-14 | Eisai R&D Man Co Ltd | Coniugati anticorpo-farmaco a base di eribulina e metodi di uso |
| TWI850223B (zh) * | 2018-03-20 | 2024-08-01 | 美商路瑪賽特有限責任公司 | 使用雷射力細胞學之先進生理及生化細胞監測與定量 |
| TWI662130B (zh) * | 2018-09-21 | 2019-06-11 | 國立臺灣大學 | 分離循環癌細胞之方法 |
| CN111019898B (zh) * | 2019-02-14 | 2023-07-21 | 中山大学孙逸仙纪念医院 | 人恶性叶状肿瘤细胞系hjp-0320及其应用 |
| CN111019897B (zh) * | 2019-02-14 | 2023-08-11 | 中山大学孙逸仙纪念医院 | 人良性叶状肿瘤细胞系glk-1010及其应用 |
| CN111019899B (zh) * | 2019-02-14 | 2023-08-04 | 中山大学孙逸仙纪念医院 | 人恶性叶状肿瘤细胞系lj-0429及其应用 |
| CN113466417B (zh) * | 2021-05-13 | 2023-03-21 | 柳州东风容泰化工股份有限公司 | 一种氟尿嘧啶的制备纯度评估方法及系统 |
| WO2024054627A1 (en) * | 2022-09-08 | 2024-03-14 | The University Of North Carolina At Chapel Hill | Diagnosis of patient tumor tissue |
| CN115747290A (zh) * | 2022-11-23 | 2023-03-07 | 零壹人工智能科技研究院(南京)有限公司 | 一种对肠癌类器官进行药敏测试的新操作方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997038313A1 (en) * | 1996-04-05 | 1997-10-16 | The Johns Hopkins University | A method of enriching rare cells |
| US6077684A (en) * | 1996-11-14 | 2000-06-20 | Vanderbilt University | Automated assay for measuring apoptosis in cell culture |
| AU2002239491A1 (en) * | 2000-11-09 | 2002-05-27 | Vanderbilt University | Methods for the treatment of cancer and other diseases and methods of developing the same |
| KR100721927B1 (ko) * | 2006-10-31 | 2007-05-28 | 이수앱지스 주식회사 | 암조직에서 암세포를 분리하는 방법 |
| IT1391619B1 (it) * | 2008-11-04 | 2012-01-11 | Silicon Biosystems Spa | Metodo per l'individuazione, selezione e analisi di cellule tumorali |
| US20110244503A1 (en) * | 2010-03-31 | 2011-10-06 | Perree Mathieu | System and Method for Anti-Cancer Drug Candidate Evaluation |
| BR112012024619A2 (pt) * | 2010-03-31 | 2016-05-31 | Diatech Oncology Llc | sistema e método para avaliação de candidato a medicamento anticancer |
| US9476871B2 (en) * | 2012-05-02 | 2016-10-25 | Diatech Oncology Llc | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
-
2013
- 2013-03-14 WO PCT/US2013/031300 patent/WO2013172955A1/en not_active Ceased
- 2013-03-14 SG SG11201407497TA patent/SG11201407497TA/en unknown
- 2013-03-14 AU AU2013263337A patent/AU2013263337A1/en not_active Abandoned
- 2013-03-14 MX MX2014013939A patent/MX2014013939A/es unknown
- 2013-03-14 HK HK15109313.4A patent/HK1208727A1/xx unknown
- 2013-03-14 CN CN201380037542.XA patent/CN104704368A/zh active Pending
- 2013-03-14 CA CA2873180A patent/CA2873180A1/en not_active Abandoned
- 2013-03-14 EP EP13790721.8A patent/EP2850434A4/en not_active Withdrawn
- 2013-03-14 BR BR112014028396A patent/BR112014028396A2/pt not_active IP Right Cessation
- 2013-03-14 IN IN9582DEN2014 patent/IN2014DN09582A/en unknown
- 2013-03-14 JP JP2015512640A patent/JP2015517662A/ja active Pending
- 2013-03-14 US US14/400,446 patent/US20150160193A1/en not_active Abandoned
- 2013-03-14 KR KR20147032343A patent/KR20150035537A/ko not_active Withdrawn
- 2013-05-13 TW TW102116888A patent/TW201409029A/zh unknown
-
2014
- 2014-11-13 IL IL235709A patent/IL235709A0/en unknown
- 2014-12-12 CO CO14273304A patent/CO7240391A2/es unknown
- 2014-12-12 CR CR20140575A patent/CR20140575A/es unknown
-
2016
- 2016-11-22 US US15/358,778 patent/US20170336391A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150160193A1 (en) | 2015-06-11 |
| KR20150035537A (ko) | 2015-04-06 |
| HK1208727A1 (zh) | 2016-03-11 |
| EP2850434A4 (en) | 2016-01-13 |
| WO2013172955A1 (en) | 2013-11-21 |
| IL235709A0 (en) | 2015-01-29 |
| IN2014DN09582A (enExample) | 2015-07-17 |
| AU2013263337A1 (en) | 2014-12-04 |
| BR112014028396A2 (pt) | 2018-05-29 |
| JP2015517662A (ja) | 2015-06-22 |
| SG11201407497TA (en) | 2014-12-30 |
| CO7240391A2 (es) | 2015-04-17 |
| EP2850434A1 (en) | 2015-03-25 |
| MX2014013939A (es) | 2015-05-11 |
| WO2013172955A9 (en) | 2014-02-27 |
| TW201409029A (zh) | 2014-03-01 |
| CA2873180A1 (en) | 2013-11-21 |
| CN104704368A (zh) | 2015-06-10 |
| US20170336391A1 (en) | 2017-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20140575A (es) | Proceso de aislamiento / purificación de células tumorales y métodos del uso del mismo | |
| HK1207000A1 (en) | Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies | |
| CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
| HK1204326A1 (en) | Enediyne compounds, conjugates thereof, and uses and methods therefor | |
| PH12014501738A1 (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| GB201106743D0 (en) | Novel compounds | |
| HK1206055A1 (en) | Methods and processes for non-invasive assessment of genetic variations | |
| WO2014080290A3 (en) | Cyclic amines as bromodomain inhibitors | |
| EA201590215A1 (ru) | Макроциклические пурины для лечения вирусных инфекций | |
| MX389061B (es) | Composiciones de nucleasa terapeuticas y metodos. | |
| HK1197273A1 (en) | Methods and materials related to ovarian cancer | |
| IN2015DN00636A (enExample) | ||
| BR112015031027A2 (pt) | Uso de um composto, método in vitro, composição farmacêutica e forma de dosagem única | |
| NZ704719A (en) | Cd133 aptamers for detection of cancer stem cells | |
| MX363270B (es) | Composiciones y metodos para inhibir la polimerasa viral. | |
| CL2015001020A1 (es) | Compuestos derivados de 4-carboxamido-isoindolinona, inhibidores selectivos de parp-1; proceso de preparacion; composicion farmaceutica; un metodo in vitro; un producto; y su uso como medicamento con actividad antineoplasica | |
| PH12014502834B1 (en) | Pharmaceutical form for extended release of active substances | |
| MX2015006986A (es) | Solucion de trombina y metodos de uso de esta. | |
| WO2013131089A3 (en) | Potent anticancer activity via dual compound activation | |
| WO2013188750A3 (en) | Substituted macrocyclic compounds having proteasome inhibitory activity | |
| MX2014015766A (es) | Receptores de tipo toll y oligonucleotidos inmunoestimuladores. | |
| WO2013190509A3 (en) | Preparation of intermediates of boceprevir | |
| UY34273A (es) | Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparación | |
| UA117455C2 (uk) | Спосіб лікування раку легенів із застосуванням інгібітора кінази аврора | |
| WO2014029888A3 (en) | Branched or macrocyclic polyamines and uses thereof |